The Coalition to Prevent Deep-Vein Thrombosis provides a list of frequently asked questions to educate people about this potentially deadly condition. DVT occurs when a blood clot forms in one of the large veins, usually in the lower limbs, leading to either partially or completely blocked circulation.
A clot can be deadly if it breaks off and travels to the lungs – a condition called pulmonary embolism.
Some of the questions and ...
continue reading...
In a piece for Forbes, writer Mark Gibbs explores the role that German corporation Bayer – a producer of pharmaceuticals and agro-chemicals — appears to be playing in the global disappearance of bee colonies.
Bayer produces nicotine-based pesticides called neonicotinoids such as imidacloprid. While harmless to humans in low doses, the chemicals are lethal to insects.
Gibbs mentions three recent studies finding that even when used properly, the chemicals are toxic to ...
continue reading...
A New York Times report from 2003 details a scandal in which pharmaceutical giant Bayer intentionally sold millions of dollars worth of AIDS-tainted medication in Asia and Latin America in the mid-1980s.
According to the report, the medicine is called Factor VIII concentrate. It effectively provides the missing ingredient without which hemophiliacs’ blood can’t clot. It was made using pools of plasma from 10,000 or more donors.
In the early days of ...
continue reading...
A story in the Tampa Bay Times warns readers that a long airplane trip can put them at risk of suffering a blood clot.
The story cites research published in the Annals of Internal Medicine, which found that taking a blood thinner – or even a baby aspirin – before such a trip may reduce that risk.
Anyone can be at a higher risk of blood clots in the legs, called deep ...
continue reading...Pharmaceutical companies and public health advocates worldwide are keeping an eye on a legal case in India, in which pharmaceutical giant Bayer is appealing a decision by the Indian patent controller to override the company’s monopoly on its cancer drug Nexavar.
If upheld, the decision will allow an Indian company to produce and sell the drug for the equivalent of $173 U.S. dollars a month, the Financial Times reports.
Bayer’s pricing would ...
continue reading...According to a Reuters story, German drug manufacturer Bayer is seeking European approval of a contraceptive skin patch.
The story notes that Bayer’s main oral contraceptive brand, Yasmin, has generated controversy over health risks. The company has so far agreed to pay a combined $400 million to settle almost one third of about 6,000 legal claims in the U.S. that Yasmin caused ...
continue reading...
